This article was originally published by Ravi Gupta, Thomas J Bollyky, Matthew Cohen, Joseph S Ross, and Aaron S Kesselheim […]
Officially known as Approved Drug Products With Therapeutic Equivalence Evaluations, the FDA Orange Book contains a list of drugs considered
3 Uses for Historical Versions of the FDA Orange Book Read Post »
While the Patent Trial and Appeal Board invalidates Orange Book-listed patents less than 20 percent of the time, it accepts
What We Know From 4-Plus Years of Drug Patent Challenges Heard by the PTAB Read Post »
Combination products have emerged as a fascinating frontier, blending the realms of pharmaceuticals, medical devices, and biotechnology. These hybrid creations
Patents for Combination Products: Challenges and Opportunities Read Post »
By Ed Lamb, DrugPatentWatch Writer Pilot projects are underway, but regulatory and stakeholder buy-in concerns remain When pharmaceutical supply chain
How Pharmaceutical Blockchain Technology Challenges Can Be Overcome Read Post »
The World Health Organization’s (WHO) Essential Medicines List (EML) serves as a cornerstone in addressing this issue, providing a blueprint
The pharmaceutical industry faces unique challenges, from stringent regulatory requirements to high failure rates in drug development. This comprehensive guide
Decision-making in product portfolios of pharmaceutical research and development Read Post »
Understanding Biobetters: The Next Generation of Biologics Imagine taking a already successful biological drug and giving it superpowers. That’s essentially
Biobetters, Supergenerics Hold Many Advantages for Pharma Companies Read Post »
The approval processes for drugs and medical devices play a crucial role in ensuring patient safety and product efficacy. As
Drugs and Devices: Comparison of European and U.S. Approval Processes Read Post »
Get fresh news and insights, drug patent expirations & more…
